Condition deep-dive · 8 min read

Recurrent UTI prevention — what the supplement evidence supports

Updated 2026-05-02 · Reviewed by SupplementScore editors · No sponsorships

Recurrent urinary tract infection — defined as two or more in six months, or three or more in a year — affects a meaningful fraction of women, especially after menopause. The supplement category around UTI prevention has more enthusiasm than evidence, but two compounds genuinely work and one prescription option is far more effective than the supplement layer.

Read this first. Active UTI symptoms — burning urination, urgency, frequency, suprapubic pain — need clinician assessment, urine culture where indicated, and antibiotic treatment. Supplements are for prevention in known recurrent-UTI patients between episodes, not for treating an active infection. Symptoms suggesting upper-tract involvement (fever, flank pain, vomiting) need urgent care, not supplement self-management. Pregnancy UTI is a separate, urgent conversation.

The supplements with the strongest prevention evidence

Tier 2 evidence · Direct E. coli adhesion blocker

D-mannose

2 g/day for prevention, ongoing; trial protocols use 2 g once daily or 1 g twice daily

D-mannose is a simple sugar that binds the FimH adhesin on uropathogenic E. coli, the bacterium responsible for ~80% of community-acquired UTIs. Bound bacteria are flushed out rather than adhering to the urinary epithelium. Multiple RCTs show prevention benefit comparable to low-dose prophylactic antibiotics in recurrent-UTI women, with substantially fewer side effects and no antibiotic-resistance pressure. Generally very well tolerated. Mild osmotic GI effects at higher doses. Limited data in pregnancy; conservative practice is to discuss with your OB.

Tier 2 evidence · PAC-standardised extracts only

Cranberry extract (PAC-standardised, ≥36 mg PAC/day)

36 mg proanthocyanidins (PAC) per day from a standardised extract — this is the trial-validated threshold

The cranberry literature is messier than the marketing suggests. The active compounds are A-type proanthocyanidins (PACs), which inhibit bacterial adhesion. The dose threshold matters: trials below 36 mg PAC/day are typically null; trials at or above the threshold are typically positive in cohort and prevention RCTs. The 2023 Cochrane review confirmed prevention benefit in women with recurrent UTI. Cranberry juice and most consumer cranberry capsules deliver too little PAC at standard servings — look explicitly for products that disclose PAC content (Ellura is a commonly-cited example at 36 mg PAC/capsule).

Tier 1 evidence · For postmenopausal women

Vaginal estrogen (prescription)

Topical estradiol cream, ring, or tablet — clinician-prescribed

Not a supplement, but worth listing because it has substantially better recurrent-UTI prevention evidence than any supplement in postmenopausal women. The mechanism — restoring vaginal lactobacillus colonisation and reducing periurethral colonisation by uropathogens — is well-established. Local (vaginal) estrogen does not carry the systemic risks of oral hormone therapy. If you are postmenopausal with recurrent UTI, this is the conversation to have first.

The supplements with smaller-but-suggestive evidence

Lactobacillus probiotics (specific strains: L. rhamnosus GR-1, L. reuteri RC-14) — small studies in oral or intravaginal protocols. Evidence base is thinner than D-mannose or cranberry. The two named strains have the most-cited UTI-specific data; generic "women's probiotic" products typically do not include them at trial-validated doses.
Vitamin D3 (in deficient patients) — observational associations between low 25-OH-D and recurrent UTI. Reasonable to replete deficiency for general health reasons; UTI-specific trial evidence is preliminary.
Methenamine hippurate — not a supplement (OTC in some jurisdictions, prescription in others). The 2022 ALTAR trial established it as non-inferior to antibiotic prophylaxis for recurrent UTI prevention, with substantially less antibiotic resistance. Worth knowing about and asking your clinician.

What to skip

Plain cranberry juice — typically PAC content too low at any reasonable serving; sugar load substantial; no consistent benefit in trials.
Generic "urinary tract support" multi-ingredient products — combine sub-therapeutic doses of cranberry, D-mannose, hibiscus, and others.
Uva ursi (bearberry) for chronic use — short-term efficacy for active symptoms is suggested in old literature, but contains hydroquinone which is hepatotoxic and potentially carcinogenic with chronic use. Not for prevention.
Hibiscus tea (high-dose extracts) — limited evidence and theoretical antiplatelet concerns at high doses.
"Alkaline" urine cleanses — alkalinisation does not improve outcomes in most UTI scenarios; the popular potassium citrate / sodium bicarbonate protocols carry their own electrolyte risks.
Colloidal silver — no evidence, real risk of permanent skin discoloration (argyria).

The non-supplement layer that matters

Several behavioural and clinical interventions have meaningful UTI-prevention evidence: post-coital voiding (small but consistent effect in women whose UTIs are sex-related), adequate fluid intake (the 2018 RCT of an extra 1.5 L/day in women with low baseline fluid intake reduced recurrence by ~50%), front-to-back wiping, avoiding spermicide-based contraception (associated with higher UTI rates). Daily prophylactic antibiotics work but build resistance and are increasingly disfavoured for long-term use. Methenamine hippurate is a reasonable non-antibiotic prescription alternative.

What to track

UTI episode count over 6-month windows. If recurrence persists despite supplement and lifestyle measures at 6 months, the conversation with urology or your primary care physician should consider methenamine hippurate, vaginal estrogen (postmenopausal), or imaging to rule out anatomic contributors.

Practical quick-start. D-mannose 2 g/day + PAC-standardised cranberry (≥36 mg PAC/day) + adequate hydration (target 2.5+ L/day) + behavioural measures. Reassess at 3 months. If postmenopausal, add the conversation with your clinician about vaginal estrogen — it tends to outperform every supplement in that population.